HER3 and mutant EGFR meet MET
- 1 June 2007
- journal article
- research article
- Published by Springer Nature in Nature Medicine
- Vol. 13 (6), 675-677
- https://doi.org/10.1038/nm0607-675
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Epidermal growth factor receptor mutations in lung cancerNature Reviews Cancer, 2007
- Novel D761Y and Common Secondary T790M Mutations in Epidermal Growth Factor Receptor–Mutant Lung Adenocarcinomas with Acquired Resistance to Kinase InhibitorsClinical Cancer Research, 2006
- Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancerJournal of Clinical Investigation, 2006
- Analysis of Epidermal Growth Factor Receptor Gene Mutation in Patients with Non–Small Cell Lung Cancer and Acquired Resistance to GefitinibClinical Cancer Research, 2006
- Invasive growth: a MET-driven genetic programme for cancer and stem cellsNature Reviews Cancer, 2006
- Clinical Course of Patients with Non–Small Cell Lung Cancer and Epidermal Growth Factor Receptor Exon 19 and Exon 21 Mutations Treated with Gefitinib or ErlotinibClinical Cancer Research, 2006
- ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell linesProceedings of the National Academy of Sciences, 2005
- EGFRMutation and Resistance of Non–Small-Cell Lung Cancer to GefitinibNew England Journal of Medicine, 2005
- Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase DomainPLoS Medicine, 2005
- Strategies to overcome resistance to targeted protein kinase inhibitorsNature Reviews Drug Discovery, 2004